Results 51 to 60 of about 238 (77)

Tremelimumab Plus Durvalumab Retreatment and 4-Year Outcomes in Patients With Mesothelioma: A Follow-Up of the Open Label, Non-Randomised, Phase 2 NIBIT-MESO-1 Study

open access: yesLancet Respiratory Medicine,the, 2021
Background: The NIBIT-MESO-1 study demonstrated the efficacy and safety of tremelimumab combined with durvalumab in patient with unresectable mesothelioma followed up for a median of 52 months [IQR 49–53].
Maresa Altomonte   +2 more
exaly   +3 more sources

Nivolumab Plus Ipilimumab in Melanoma Patients With Asymptomatic Brain Metastases: 7-Year Outcomes and Quality of Life From the Multicenter Phase III NIBIT-M2 Trial [PDF]

open access: yesEuropean Journal of Cancer
Background: The primary analysis of the phase III NIBIT-M2 study showed a 41% 4-year overall survival (OS) of melanoma patients with asymptomatic brain metastases treated with ipilimumab plus nivolumab.
Michele Maio   +2 more
exaly   +3 more sources

Three-Year Follow-Up of Advanced Melanoma Patients Who Received Ipilimumab Plus Fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 Phase II Study

open access: yesAnnals of Oncology, 2015
Background: In the NIBIT-M1 study, we reported a promising activity of ipilimumab combined with fotemustine in metastatic melanoma (MM) patients with or without brain metastases.
Mario Santinami   +2 more
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

Ipilimumab and Fotemustine in Patients With Advanced Melanoma (NIBIT-M1): An Open-Label, Single-Arm Phase 2 Trial

Lancet Oncology, The, 2012
Ipilimumab improves survival of patients with metastatic melanoma, many of whom develop brain metastases. Chemotherapy-induced release of tumour antigens might amplify ipilimumab's antitumour activity. We aimed to investigate the efficacy and safety of ipilimumab plus fotemustine in patients with metastatic melanoma with or without asymptomatic brain ...
Pier Francesco Ferrucci   +2 more
exaly   +8 more sources

A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial

Journal of Clinical Oncology, 2011
TPS230 Background: CTLA-4 blockade by monoclonal antibodies (mAb) up-regulates host’s immune response(s) through the inhibition of negative signals delivered to T lymphocytes by the engagement with...
Di Giacomo AM   +9 more
openaire   +5 more sources

Tremelimumab Combined With Durvalumab in Patients With Mesothelioma (NIBIT-MESO-1): An Open-Label, Non-Randomised, Phase 2 Study

Lancet Respiratory Medicine,the, 2018
Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first-line or second-line chemotherapy compared with placebo in the DETERMINE study.
Maresa Altomonte   +2 more
exaly   +6 more sources

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012

Cancer Immunology, Immunotherapy, 2013
Cancer immunology ...
Maio, M.   +47 more
openaire   +4 more sources

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

Cancer Immunology, Immunotherapy, 2018
A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of ...
Michele Maio   +14 more
openaire   +5 more sources

Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: The NIBIT-MESO-1 study.

Journal of Clinical Oncology, 2016
TPS8575Background: Malignant mesothelioma (MM) has a very dismal prognosis and treatment of MM patients remains largely unsatisfactory; thus, new therapeutic approaches are eagerly awaited.
Luana Calabrò   +8 more
openaire   +1 more source

Home - About - Disclaimer - Privacy